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AbsTrACT
The number of laser in situ keratomileusis (LASIK) 
procedures is continuing to rise. Since its first application 
for correcting simple refractive errors over 25 years 
ago, the role of LASIK has extended to treat other 
conditions, including postkeratoplasty astigmatism/
ametropia, postcataract surgery refractive error and 
presbyopia, among others. The long-term effectiveness, 
predictability and safety have been well established by 
many large studies. However, due to the creation of a 
potential interface between the flap and the underlying 
stroma, interface complications such as infectious 
keratitis, diffuse lamellar keratitis and epithelial ingrowth 
may occur. Post-LASIK epithelial ingrowth (PLEI) is an 
uncommon complication that usually arises during the 
early postoperative period. The reported incidence of PLEI 
ranged from 0%–3.9% in primary treatment to 10%–20% 
in retreatment cases. It can cause a wide spectrum 
of clinical presentations, ranging from asymptomatic 
interface changes to severe visual impairment and 
flap melt requiring keratoplasty. PLEI can usually be 
treated with mechanical debridement of the affected 
interface; however, additional interventions, such as 
alcohol, mitomycin C, fibrin glue, ocular hydrogel sealant, 
neodymium:yttriumaluminum garnet laser and amniotic 
membrane graft, may be required for recurrent or 
refractory cases. The aims of this review are to determine 
the prevalence and risk factors of PLEI; to describe its 
pathogenesis and clinical features and to summarise the 
therapeutic armamentarium and the visual outcome of 
PLEI.
InTroduCTIon
The history of modern-day laser in situ 
keratomileusis (LASIK) dates back to 1985 
when Peyman first introduced the concept 
of performing laser ablation under a corneal 
flap.1 In 1990, Pallikaris et al2 performed the 
first LASIK procedure in a rabbit model using 
a modified microkeratome for corneal flap 
creation coupled with excimer laser. To date, 
LASIK remains the most widely performed 
laser refractive surgery worldwide, with over 
1.2 million LASIK surgeries being performed 
annually in the USA and Europe.3 
Since its introduction, the role of LASIK 
has expanded from the initial correction of 
simple refractive errors to other clinical and 
refractive indications, including the manage-
ment of postkeratoplasty astigmatism/
ametropia, postcataract surgery refractive 
error and presbyopia, among others.4–7 The 
long-term effectiveness, predictability and 
safety of LASIK have been well established by 
many long-term studies.8 9 A recent systematic 
review of LASIK in 67 893 eyes reported excel-
lent visual and refractive outcomes with very 
high patient satisfaction following modern 
LASIK surgery; 99.5% of patients achieved 
uncorrected distance visual acuity of 6/12 or 
better and 98.6% of patients achieved spher-
ical equivalent refraction within ±1.0 dioptre 
(D) of target refraction.10
Nonetheless, the creation of an inter-
face between the flap and the underlying 
corneal stroma can lead to flap-related and 
flap-stromal interface complications such as 
flap dislocation, infectious keratitis, diffuse 
lamellar keratitis and epithelial ingrowth 
(EI). Post-LASIK epithelial ingrowth (PLEI) 
is a rare complication that is characterised 
by the ingrowth of corneal epithelium at 
the interface between the flap and stromal 
bed following LASIK, leading to a range of 
symptoms and signs. In view of its low preva-
lence, the experience of treating EI is largely 
based on anecdotal case reports and small 
case series. The aims of this review are three-
fold: first, to determine the prevalence and 
risk factors of PLEI; second, to describe the 
pathogenesis and clinical features of EI and 
third, to summarise the therapeutic arma-
mentarium and the visual outcome of PLEI.
PrevAlenCe of ePIThelIAl IngrowTh 
followIng lAsIK And oTher TyPes of 
surgery
The prevalence of EI following primary 
LASIK is very low, estimated between 0% 
and 3.9%.11–15 However, the risk of EI is 
significantly increased in various clinical 
circumstances, especially when the flap is 
lifted for retreatment (up to 10%–20%).16–18 
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EI has also been rarely reported following trauma and 
other types of ocular surgery, including penetrating 
trauma, keratoplasty, cataract and pterygium surgery.19–21 
Such manifestation is due to the inadvertent introduc-
tion of corneal epithelial cells into the intraocular 
environment, resulting in proliferation of epithelial cells 
on the surface of intraocular structures such as posterior 
cornea, anterior chamber angle, ciliary body, iris and lens 
capsule.
rIsK fACTors of PosT-lAsIK ePIThelIAl IngrowTh
Although the risk of PLEI is low, clinical management 
can be very challenging in some cases. The risk factors 
for PLEI are summarised in box 1. A thorough under-
standing of these risk factors enables better preoperative 
patient counselling and risk assessment. 
Modifiable factors
Several modifiable factors of PLEI have been described 
in the literature; these include surgical instrumentation, 
retreatment technique and conformation of LASIK flap 
hinge.
Surgical instrumentation
Flap creation by femtosecond laser or microkeratome 
represents one of the major steps in LASIK surgery. Some 
studies have suggested that the instruments used during 
flap creation could influence the risk of PLEI.18 22 23 Letko 
et al18 observed that the risk of EI following LASIK flap-
lift for retreatment was significantly lower in patients who 
were initially treated with femtosecond LASIK (f-LASIK; 
1.4%) as compared with microkeratome-assisted LASIK 
(m-LASIK; 8.3%). In another study of 6415 eyes that 
underwent f-LASIK, the risk of PLEI was reported to be as 
low as 0.03%.23 It was postulated that the lower incidence 
of PLEI following f-LASIK was attributed to the geometry 
of the flap edge and the lower risk of peripheral trauma 
at the flap edge.
Surgical technique during LASIK retreatment
Although the long-term efficacy and stability of LASIK 
surgery have been reported in the published literature, 
retreatment is occasionally required in some cases due 
to regression or inadequacy of the treatment effect.24 25 
Flap lift for retreatment is a well-recognised risk factor for 
PLEI. Nonetheless, Chan and Boxer Wachler26 observed 
that using a Pinelli spatula to cleave the circumference 
of the flap edge before lifting the flap could significantly 
reduce the risk of PLEI when compared with direct flap 
lifting using forceps. It was suggested that the use of 
spatula reduced the risk of trauma to the corneal epithe-
lium at the flap edge. On the other hand, the risk of EI 
associated with LASIK retreatment could be eliminated 
by employing photorefractive keratectomy over the 
previous LASIK flap as a retreatment strategy, obviating 
the need of flap lifting for retreatment.16
Conformation of LASIK flap edge
The conformation of LASIK flap edge may also have an 
effect on the risk of PLEI. In a rabbit model, Jhanji et 
al27 reported that PLEI was more frequently observed in 
flaps with 70° (conventional) side cuts compared with 
flaps with 115° (inverted) side cuts. In addition, corneas 
with 70° side cuts showed significantly increased apop-
totic cells compared with the inverted side-cuts corneas. 
Asano-Kato et al28 similarly reported a greater incidence 
of PLEI using MK-2000 microkeratome (Nidek, Aichi, 
Japan) compared with LSK-One microkeratome (Moria, 
Antony, France) due to the difference in flap edges.
Corneal epithelial injury
Asano-Kato et al28 and Jabbur et al29 have reported that 
intraoperative epithelial injury/defect is a risk factor 
of PLEI. Similarly, Wang and Maloney15 observed that 
33% of their patients who had a postoperative epithelial 
defect subsequently developed PLEI. They observed that 
patients with epithelial basement membrane dystrophy 
had a higher recurrence rate of PLEI, requiring multiple 
surgical debridement. They proposed that the epithelial 
defect resulted in flap hydration/oedema, ultimately 
leading to a poor adhesion of the flap-stromal interface 
with PLEI.
LASIK flap dislocation
LASIK flap dislocation is a recognised risk for PLEI.30 31 It 
shares the similar principle with cases of flap-lift retreat-
ment where the corneal epithelial cells at the flap-host 
junction are given access to the flap-stromal interface due 
to poor adhesion/dislocation of the flap edge. There-
fore, the development of late-onset PLEI should raise the 
Box 1 Modifiable and non-modifiable risk factors of 
epithelial ingrowth following lAsIK
Modifiable risk factors
1. Surgical instrumentation
 – m-LASIK>f-LASIK in risk of PLEI following primary and 
enhancement treatment
2. Surgical technique during retreatment
 – Direct flap lift with forceps>cleaving with spatula before lifting
3. Conformation of LASIK flap edge
 – 70° side cut>115° side cut
4. Corneal epithelial injury
5. LASIK flap dislocation
non-modifiable risk factors
1. Patient  factors 
 – Increased age (weak evidence)
 – Type  1  diabetes mellitus
 – Corneal epithelial basement membrane dystrophy or recurrent 
corneal erosion syndrome
2. Types of refractive correction 
 – Hyperopic LASIK > myopic  LASIK
3. Flap lift for retreatment 
PLEI, post-LASIK epithelial ingrowth; LASIK, laser  in situ   keratomileusis; 
m-LASIK, microkeratome-assisted LASIK; f-LASIK, femtosecond LASIK.
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suspicion of occult dislocation of the LASIK flap and a 
history of trauma should be elicited.31
non-modifiable factors
Several non-modifiable factors have also been described 
in the literature. These include patient demographics, 
preoperative refractive errors and primary and retreat-
ment procedures.
Patient factors
One study of 30 eyes suggested that older age might 
increase the risk of PLEI.26 However, this was not observed 
in a larger study that included 4500 LASIK eyes.12 Simi-
larly, there is no clear gender or race predilection for 
PLEI.12 In terms of ocular factors, various studies have 
demonstrated the positive association between PLEI and 
corneal epithelial basement membrane dystrophy.15 29 
Systemic factor such as type 1 diabetes mellitus may also 
increase the risk of PLEI.29
Hyperopic versus myopic LASIK
Hyperopic LASIK has been associated with a higher risk of 
PLEI as compared with myopic LASIK.11 32 In a retrospec-
tive study of 1000 m-LASIK procedures, Mohamed et al11 
had observed a significant higher risk of PLEI in patients 
who were undergoing hyperopic LASIK as opposed to 
myopic LASIK. The incidence of PLEI following hyper-
opic LASIK was seven times higher than myopic LASIK 
(23% vs 3%) and the increased risk was observed in 
both primary (17% vs 3%) and enhancement treatment 
(43% vs 7%).11 This may be related to the fact that laser 
ablation is applied at the mid-periphery of the cornea in 
hyperopic LASIK as opposed to the central of the cornea 
in myopic LASIK. The conformational change in the 
mid-periphery of the cornea (closer to the flap edge) can 
potentially affect the flap-stromal adhesion, increasing 
the risk of PLEI.
Primary versus retreatment LASIK
Although LASIK surgery has a well-established long-term 
effectiveness and refractive stability, approximately up 
to 10%–14% of the patients may undergo retreatment/
enhancement at some stage following their initial LASIK 
surgery.15 33–35 LASIK flap lifts for retreatment increases 
the risk for EI with the reported incidence ranging from 
1.7% to 23.3% when compared with 0% to 3.9% for 
primary treatments.11–18 33 Moreover, flap-lift retreatment 
performed three or more years after primary LASIK carry 
a higher risk of clinically significant PLEI compared with 
retreatments with flap lifts done earlier.12
PAThogenesIs of PosT-lAsIK ePIThelIAl IngrowTh And 
CorneAl wound heAlIng
The pathogenesis of PLEI is attributed to two underlying 
mechanisms. Implantation of the corneal epithelial cells 
during the flap creation, resulting in epithelial nests away 
from the flap edge. These epithelial cells usually have 
minimal proliferative ability due to limited nourishment 
from the ocular surface environment and may remain 
asymptomatic. Second, PLEI may be a consequence of 
corneal epithelial cells migrating from the flap edge 
towards the flap-stromal interface due to poor flap adhe-
sion, flap dislocation or presence of foreign bodies (eg, 
blood, cell infiltrate, ointment, etc) at the flap-stromal 
interface.15 28 In this instance, the poorly attached or 
dislocated flap allows the invasion of epithelial cells into 
the interface. Subsequently, these invaded cells lift up 
the edge of the flap, causing pooling of the fluorescein.15 
Proliferation of the invaded epithelial cells culminates in 
the formation of a fistula, resulting in progressive PLEI. 
Interestingly, the histopathological findings of PLEI 
differs in early and late stages according to a Japanese 
study.36 It was shown that early PLEI comprised multilay-
ered squamous epithelium resembling normal corneal 
epithelium, whereas late PLEI consisted of clumps 
containing amorphous materials with little cellular 
elements, potentially reflecting different proliferative 
activity of EI at different stages.36
Various studies have shown that the corneal wound 
healing following LASIK primarily occurs at the periphery 
of the LASIK flap-corneal stromal junction.37 38 This 
healing phenomenon explains the late onset of LASIK 
flap dislocation, even over a decade after the initial 
LASIK surgery.31 Therefore, the development of late-
onset of PLEI in a patient with previous LASIK surgery 
should raise the suspicion of occult traumatic dislocation 
of LASIK flap.
ClAssIfICATIon
Based on the location, clinical features and severity, PLEI 
can be categorised into four grades using the Prosbt/
Machat classification (table 2).39 This classification serves 
as a useful aid for consistent and standardised grading/
assessment and provides guidance on the treatment strat-
egies.
ClInICAl feATures And AssessMenT
A wide spectrum of clinical presentations has been 
reported in the literature; these range from asymptom-
atic corneal changes to severe visual impairment and flap 
melt requiring keratoplasty. The onset of PLEI usually 
takes place within a month following primary or enhance-
ment LASIK.15 However, many patients are asymptomatic 
from PLEI, explaining the wide range of time interval 
between the initial LASIK surgery and presentation of 
PLEI (0.5–108 months).40 Rapuano reported in his study 
that as many as 64% of the eyes affected by PLEI did not 
require any intervention.40 These patients usually have 
PLEI within 2 mm from the flap edge (Prosbt/Machat 
grade 1) with no visual symptoms. In some cases, patients 
may experience foreign body sensation and glare due to 
ocular surface irregularity secondary to PLEI.
In terms of clinical features, Wang and Maloney15 have 
described four key clinical signs/characteristics that 
could aid in the diagnosis of PLEI. These include epithe-
lial Pearls/nest in the interface (figure 1A), fluorescein 
pooling at the edge of the flap (due to elevation of flap 
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edge by underlying invading epithelial cells), white 
fibrotic demarcation line and keratolysis/melting of the 
flap edge. Other signs include diffuse opaque epithelial 
ingrowth (figure 1B), rolled up flap edge with thickened 
whitish-grey appearance, staining channels and periph-
eral confluent haze.
In addition to slit lamp examination, other investi-
gative tools can be used to assist in the assessment and 
monitoring of PLEI. Anterior segment optical coherence 
tomography serves as a useful investigation in detecting 
subtle PLEI changes that are not readily evident on slit 
lamp examination (figure 1C-D). Corneal topography/
tomography can be used to assess the PLEI-induced 
refractive changes and ocular surface irregularity. In 
addition, corneal densitometry using Scheimpflug 
tomography can be used to provide objective quantifica-
tion and monitoring of the severity and progression of 
EI.41
TreATMenT ModAlITIes
The indications for medical or surgical treatment of PLEI 
are largely guided by the patient’s symptoms, location 
and severity of the PLEI, and the presence of any asso-
ciated pathology such as flap dislocation/dehiscence. In 
most cases, PLEI can be surgically removed with mechan-
ical debridement of the interface; however, clinically 
significant recurrence may be as high as 36% after such 
treatment.42 The visual outcomes, recurrence rate and 
complication of various treatment modalities of PLEI are 
summarised in table 3.13 15 40 42–60
The most common treatment strategy for PLEI is 
mechanical debridement of the EI from the flap-stromal 
interface and from the inner side of the flap followed 
by careful repositioning of the flap and avoidance of any 
intraoperative/postoperative epithelial trauma.15 40 42 
Flap suturing, fibrin glue and ocular hydrogel sealant at 
the flap edge have been proposed to facilitate secured 
flap adhesion.13 40 43 46–53 In refractory cases, various 
adjunctive therapies can be used to help eradicate PLEI. 
Amniotic membrane graft (AMG) may be used in cases 
of PLEI associated with flap injury or melting.54–56 In 
addition, the use of non-invasive neodymium:yttrium 
aluminum garnet (Nd:YAG) laser has also been reported 
as a novel technique for treating PLEI.58–60
recommendation
Based on the available evidence in the literature, we 
recommend simple mechanical debridement in the first 
presentation of PLEI. Mechanical debridement can be 
performed using non-shredding spears, spatula or other 
appropriate instruments. A bandage contact lens should 
be placed to protect the flap and reduce the risk of flap 
dehiscence/dislocation,15 40 50 although there was a small 
study of 30 eyes reporting an increased risk of PLEI with 
bandage contact lens use.26 All patients should be coun-
selled on the risk of recurrence of EI (0%–36%) following 
the treatment, which may require further debridement. 
In patients with one or more episodes of recurrent EI, 
adjunctive therapies need to be administered to reduce 
further risk of recurrence. Various strategies have been 
described in the literature but many of the studies are 
of anecdotal case reports and small case series. Based on 
the evidence from larger studies (≥10 treated eyes), we 
recommend the use of either flap suturing with 10’0 nylon 
or fibrin glue to achieve secured flap-stromal adhesion. 
The recurrence rates following these treatment strategies 
range between 0%–33% and 0%–7.7%, respectively. The 
low recurrence rate of PLEI following the application of 
fibrin glue is likely attributed to its inhibitory property 
on the migration of ocular surface epithelial cells.61 In 
addition, antimetabolite, such as mitomycin C 0.02%, 
and AMG can be used to treat refractory cases and those 
associated with flap melt/injury, respectively. For patients 
who are unable to tolerate surgery, Nd:YAG laser using 
low energy of (0.6 mJ on average) can be applied as 
an alternative treatment. However, the experience and 
Table 2 Probst/Machat classification of epithelial ingrowth (adapted and modified from Neff and Probst)39
Grade Signs Progressive Location Management
1 Thin growth, 1–2 cells thick, non-progressive, 
difficult to detect, well-delineated white line 
along advancing edge, no flap change
No 2 mm within flap edge No treatment required
 2 Thicker growth, discrete cells within 
epithelial nest, no demarcation line along 
nest, easily detectable on slit lamp, rolled or 
grey flap edge with no melt
Usually (but slowly) 2 mm within flap edge Non-urgent treatment 
within 2–3 weeks
3 Pronounced growth, several cells thick, 
opaque ingrowth, geographic areas of 
necrotic cells with no demarcation line, 
flap rolled with thickened whitish-grey 
appearance, peripheral confluent haze at 
flap edge
Yes >2 mm from flap edge Urgent treatment
4 Aggressive growth, strands of epithelial cells 
invading towards visual axis, may result in 
flap melt
Yes Threatening/
affecting visual axis
Urgent treatment
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evidence is limited to one large case series of 30 eyes and 
a few case reports, and care needs to be taken during the 
procedure to avoid any flap complication. In addition, 
40% or more patients require repeat treatment to elimi-
nate the EI completely.
TreATMenT CoMPlICATIons
The most common complication following the treat-
ment of PLEI is recurrence of EI, usually recurring at 
the original area of PLEI. Risk factors for recurrence 
include infectious aetiology of EI, use of microkeratome 
for primary LASIK, hyperopic LASIK and previous 
history of recurrence.40 42 43 Based on large case series, 
the recurrence rate following treatment, depending on 
the treatment strategy and follow-up duration, ranged 
between 0% and 36% (table 3). Mechanical debride-
ment of both the interface and the inner aspect of the 
flap followed by the application of fibrin glue appears to 
have the lowest recurrence rate of PLEI as compared with 
other treatment modalities. Other uncommon compli-
cations such as diffuse lamellar keratitis and flap melt 
(up to 80% of the flap) have been reported following 
the use of highly concentrated ethanol (50%–100%) at 
the flap-stromal interface.6 62 Non-invasive Nd:YAG laser 
treatment of PLEI may also lead to localised flap melt, 
flap surface breakthrough and inadvertent creation of 
new channel at the flap edge, resulting in new areas of 
EI.63 64
vIsuAl ouTCoMe And PrognosIs
The visual outcome of PLEI is largely dependent on 
the location and the severity of the ingrowth (Probst/
Machat classification). However, PLEI is often not 
graded according to the classification, but by the need 
for intervention, in many studies (eg, whether PLEI is 
clinically significant to warrant removal). Therefore, 
Figure 1 (A) Slit lamp photography showing an area of epithelial nest/ingrowth at the flap-stromal interface (red, up arrow) 
associated with a dislocated, infolded superior temporal LASIK flap (blue, left arrows). (B) Slit lamp photography showing 
diffuse opaque epithelial ingrowth (red, left arrows) associated with occult traumatic dislocation of LASIK flap. (C) Slit lamp 
photography showing an apparently clear cornea after removal of epithelial ingrowth. (D) However, subtle residual epithelial 
ingrowth (yellow, up arrows) was identified on anterior segment optical coherence tomography (AS-OCT). At 3-month 
postremoval of epithelial ingrowth, there was a recurrence of epithelial ingrowth (visible on slit lamp examination) at the same 
area highlighted by the AS-OCT.
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by definition, patients who require surgical/proce-
dural intervention have PLEI of grade 2 or more. In 
addition, the visual outcome may be confounded 
by publication bias (eg, only studies with good visual 
outcome are published).
Patients with grade 1 PLEI (within 2 mm of flap 
edge without any problem with the flap edge) are 
usually asymptomatic with unaffected vision. Rapuano 
has reported that 64% of his patients with PLEI were 
managed with simple observation.40 In grade 2 and 
grade 3 PLEI, good visual outcome is normally retained 
following appropriate treatment. Based on larger 
studies (≥10 treated eyes), patients with PLEI usually 
achieved uncorrected distance visual acuity of ≥6/12 (in 
74%–80% cases) and ≥6/7.5 (in 45%–53% cases), and 
corrected distance visual acuity of ≥6/12 (in 77%–91% 
cases) and ≥6/7.5 (in 78%–85% cases) following treat-
ment. Central involvement of the cornea serves as the 
poor visual prognostic factor for PLEI.42 In extreme 
cases of flap melt (grade 4), significant flap-stromal 
interface scarring or aggressive PLEI, flap amputation 
or penetrating keratoplasty may be required to improve 
Table 3 The summary of visual outcomes, recurrence rate and complications of various treatment modalities for postlaser in 
situ keratomileusis (LASIK) epithelial ingrowth
Treatment Study (year)
No. of 
eyes Visual outcomes R* F/U, months (SD) Complications
MD only Wang and Maloney (2000)15 43 91% retained CDVA 
postoperatively
23% – None
Rapuano† (2010)40 4 CDVA=100%≥ 6/12; 
25%≥ 6/7.5
0% 16.5 (18.9) None
Henry et al (2012)42 45 UDVA=53%≥ 6/7.5; 
CDVA=78%≥ 6/7.5
36% 12 None
MD+diluted ethanol Anderson and Hardten‡ (2003)43 3 – 100% 5 None
MD+50% ethanol Haw and Manche (2001)44 4 CDVA=100%≥ 6/7.5 0% 3 2 DLK, resolved 
with topical CS 
MD+70% isopropyl alcohol Lahners et al (2005)45 22 – 36% - None 
MD+ocular hydrogel 
sealant
Ramsook and Hersh (2015)46 2 CDVA=100%≥ 6/9 0% 1.5 None
Yesilirmak et al (2015)47 1 CDVA=6/6 0% 6 None
MD+FG Anderson and Hardte‡ (2003)43 3 CDVA=100%≥ 6/6 0% 5 None
Yeh et al (2006)48 1 UDVA=6/21 0% 20 None 
Hardten et al (2015)49 39 UDVA=74%≥ 6/12; 
CDVA=85% ≥ 6/7.5 
7.70% 26.6 (17.0) None 
MD+FG+70% ethanol+
0.02% MMC
Wilde et al (2017)50 4 CDVA=100≥ 6/9 0% 11.8 None
MD+FS Rojas et al (2004)51 20 UDVA=45%≥ 6/6, 80%≥ 
6/12
0% 10.5 (14.3) None
Rapuano† (2010)40 9 UDVA=67%≥ 
6/12;CDVA=67%≥ 6/12 
22% 16.5 (18.9) 1 mild flap 
necrosis 
Güell et al (2014)13 13 Mean UDVA=6/7.5 0% 12 None
MD+FS+proparacaine Spanggord et al (2005)52 6 CDVA=67%≥ 6/12 33% 12 None
MD+FS+FG Narváez et al (2006)53 1 CDVA=6/6 0% 15 None
MD+AMG±FS±ethanol Lee et al (2006)54 1 CDVA=6/9 0% 7 None
Azar et al (2010)55 1 UDVA=6/7.5 0% 6 None
Kwon et al (2016)56 1 CDVA=6/6 0% 5 None
MD+PTK Fagerholm et al (2004)57 5 CDVA=100%≥ 6/12 20% – None
MD+PTK+AMG Lee et al (2006)54 1 UDVA=6/6 0% 4 None
Nd:YAG laser Ayala et al (2008)58 30 80% disappearance of 
PLEI
0% 24 None
Lindfield et al (2012)59 CDVA=100%≥ 6/5 0% 12 None
Kim et al (2014)60 2 UDVA=6/6 0% 9 None
The majority of studies that specifically evaluated the treatment outcome of significant post-LASIK epithelial ingrowth (PLEI) are included in this table.
*Recurrence refers to rate of significant recurrence of epithelial ingrowth following the initial treatment.
†Rapuano reported 13 eyes of PLEI that underwent mechanical debridement, with 9 eyes being treated with additional flap suturing.
‡This study included three patients who were all initially treated with MD and diluted ethanol. However, all of them had a significant recurrence of 
epithelial ingrowth which required a further MD and application of fibrin glue.
AMG, amniotic membrane graft; CDVA, corrected distance visual acuity; CS, corticosteroids; DLK, diffuse lamellar keratitis; FG, fibrin glue; FS, flap 
suturing; MD, mechanical debridement; MMC, mitomycin C; Nd:YAG, neodymium: yttrium aluminum garnet; PTK, phototherapeutic keratectomy; 
UDVA, uncorrected distance visual acuity.
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the vision and eradicate persistent PLEI.65–67 On the 
other hand, a rare case of spontaneous resolution of 
PLEI has been reported in the literature.68
ConClusIon
With the continuing rise of LASIK procedures, it is 
important for all ophthalmologists to become competent 
in recognising and/or managing post-LASIK complica-
tions, including PLEI. Understanding of both modifiable 
and non-modifiable risk factors helps reduce the inci-
dence of PLEI and also enables better patient counselling 
preoperatively. When appropriately managed, good 
visual prognosis is usually achieved in patients with PLEI. 
However, additional measures and interventions may be 
required in aggressive or refractory PLEI cases in order 
to achieve complete and permanent eradication of the 
disease.
MeThod of lITerATure seArCh
A literature search in PubMed electronic database was 
conducted to identify all articles concerning EI following 
LASIK. Abstracts were further reviewed and the refer-
ence lists were hand-searched to ensure complete 
inclusion of all relevant articles. Only articles published 
in English were included. Certain keywords, including 
epithelial ingrowth, epithelial downgrowth, laser in situ 
keratomileusis and LASIK, were used during the litera-
ture search.
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